Study : Sinovac Vaccine does not provide enough antibodies to neutralise Omicron
The vaccine made by Sinovac Biotech Ltd., one of the most widely used in the world, doesn’t provide sufficient antibodies to neutralise the Omicron variant, said Hong Kong researchers in initial lab findings.
Among a group of 25 people fully vaccinated with Sinovac’s shot, which is called Coronavac, none showed sufficient antibodies in their blood serum to neutralise the omicron variant, said a statement from a team of researchers at the University of Hong Kong.
Meanwhile, a latest Israeli study had revealed that a three-shot course of the Pfizer-BioNTech Covid vaccine offers protection against the new variant.
The scientists also advised members of the public to get a third vaccine dose as soon as possible, while awaiting the next generation of shots.
Whether a third dose of the present Coronavac will improve the neutralising antibody response against the Omicron variant remains to be determined.